IL301948B2 - Anti-cd3 antibody formulations - Google Patents
Anti-cd3 antibody formulationsInfo
- Publication number
- IL301948B2 IL301948B2 IL301948A IL30194823A IL301948B2 IL 301948 B2 IL301948 B2 IL 301948B2 IL 301948 A IL301948 A IL 301948A IL 30194823 A IL30194823 A IL 30194823A IL 301948 B2 IL301948 B2 IL 301948B2
- Authority
- IL
- Israel
- Prior art keywords
- antibody formulations
- antibody
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380652P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/049211 WO2018044948A1 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL301948A IL301948A (en) | 2023-06-01 |
| IL301948B1 IL301948B1 (en) | 2024-05-01 |
| IL301948B2 true IL301948B2 (en) | 2024-09-01 |
Family
ID=59858782
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301948A IL301948B2 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
| IL264502A IL264502B2 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264502A IL264502B2 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10688186B2 (en) |
| EP (1) | EP3504241B1 (en) |
| JP (3) | JP7057360B2 (en) |
| CN (2) | CN116617387A (en) |
| AU (1) | AU2017319318B2 (en) |
| CA (1) | CA3032596A1 (en) |
| DK (1) | DK3504241T3 (en) |
| IL (2) | IL301948B2 (en) |
| WO (1) | WO2018044948A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301948B2 (en) | 2016-08-29 | 2024-09-01 | Tiziana Life Sciences Plc | Anti-cd3 antibody formulations |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2020073087A1 (en) * | 2018-10-09 | 2020-04-16 | Monash University | Combination therapy for treatment and prevention of autoimmune and inflammatory diseases |
| EP3873521A2 (en) | 2018-10-31 | 2021-09-08 | Tiziana Life Sciences PLC | Composition and methods of treating inflammatory and autoimmune diseases |
| BR112021022682A2 (en) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
| EP4017526A1 (en) | 2019-08-20 | 2022-06-29 | Precision BioSciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| CA3169827A1 (en) * | 2020-03-10 | 2021-09-16 | Kunwar Shailubhai | Compositions of il-6/il-6r antibodies and methods of use thereof |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
| US20220332822A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| WO2023218100A1 (en) * | 2022-05-13 | 2023-11-16 | Tiziana Life Sciences Plc | Nasal formulations of foralumab |
| WO2024026355A1 (en) * | 2022-07-27 | 2024-02-01 | Celldex Therapeutics, Inc. | Anti-kit antibody formulations and methods |
| WO2024052445A1 (en) | 2022-09-09 | 2024-03-14 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist |
| WO2024165671A1 (en) | 2023-02-08 | 2024-08-15 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
| WO2024182767A1 (en) | 2023-03-01 | 2024-09-06 | Provention Bio, Inc. | Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil |
| JP7548475B1 (en) | 2023-03-16 | 2024-09-10 | 小野薬品工業株式会社 | Antibody preparations |
| WO2024190892A1 (en) * | 2023-03-16 | 2024-09-19 | 小野薬品工業株式会社 | Antibody preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033230A2 (en) * | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-cd3 antibody formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040037826A1 (en) | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
| US20030235583A1 (en) | 2002-06-14 | 2003-12-25 | Jeppe Sturis | Combined use of a modulator of CD3 and a beta cell resting compound |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| JP5490714B2 (en) * | 2007-11-28 | 2014-05-14 | メディミューン，エルエルシー | Protein preparation |
| EP2342231A1 (en) * | 2008-09-26 | 2011-07-13 | Roche Glycart AG | Bispecific anti-egfr/anti-igf-1r antibodies |
| JP2012530721A (en) * | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | Lyophilized formulations for small module immunity drugs |
| AR078161A1 (en) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD |
| JP2013515754A (en) | 2009-12-29 | 2013-05-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Novel antibody formulation |
| UA118028C2 (en) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
| IL301948B2 (en) | 2016-08-29 | 2024-09-01 | Tiziana Life Sciences Plc | Anti-cd3 antibody formulations |
-
2017
- 2017-08-29 IL IL301948A patent/IL301948B2/en unknown
- 2017-08-29 US US15/690,192 patent/US10688186B2/en active Active
- 2017-08-29 CA CA3032596A patent/CA3032596A1/en active Pending
- 2017-08-29 CN CN202211674110.7A patent/CN116617387A/en active Pending
- 2017-08-29 CN CN201780052970.8A patent/CN109843920B/en active Active
- 2017-08-29 EP EP17765519.8A patent/EP3504241B1/en active Active
- 2017-08-29 WO PCT/US2017/049211 patent/WO2018044948A1/en unknown
- 2017-08-29 IL IL264502A patent/IL264502B2/en unknown
- 2017-08-29 JP JP2019531579A patent/JP7057360B2/en active Active
- 2017-08-29 AU AU2017319318A patent/AU2017319318B2/en active Active
- 2017-08-29 DK DK17765519.8T patent/DK3504241T3/en active
-
2020
- 2020-05-18 US US16/876,839 patent/US20210000957A1/en active Pending
-
2022
- 2022-04-07 JP JP2022063973A patent/JP7461401B2/en active Active
-
2024
- 2024-03-22 JP JP2024046063A patent/JP2024075713A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033230A2 (en) * | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-cd3 antibody formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7461401B2 (en) | 2024-04-03 |
| US20180177880A1 (en) | 2018-06-28 |
| US10688186B2 (en) | 2020-06-23 |
| JP7057360B2 (en) | 2022-04-19 |
| IL301948B1 (en) | 2024-05-01 |
| CN109843920A (en) | 2019-06-04 |
| IL264502B2 (en) | 2023-09-01 |
| CN116617387A (en) | 2023-08-22 |
| WO2018044948A1 (en) | 2018-03-08 |
| US20210000957A1 (en) | 2021-01-07 |
| CA3032596A1 (en) | 2018-03-08 |
| CN109843920B (en) | 2023-01-13 |
| JP2022082757A (en) | 2022-06-02 |
| DK3504241T3 (en) | 2024-08-19 |
| AU2017319318A1 (en) | 2019-02-21 |
| EP3504241A1 (en) | 2019-07-03 |
| EP3504241B1 (en) | 2024-05-15 |
| AU2017319318B2 (en) | 2024-09-19 |
| IL264502B1 (en) | 2023-05-01 |
| EP4406554A2 (en) | 2024-07-31 |
| IL264502A (en) | 2019-02-28 |
| IL301948A (en) | 2023-06-01 |
| JP2024075713A (en) | 2024-06-04 |
| JP2019526627A (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264502B1 (en) | Anti-cd3 antibody formulations | |
| IL264159A (en) | Anti-tim-3 antibodies | |
| IL267797A (en) | Anti-gpc3 antibody | |
| GB201601073D0 (en) | Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| ZA201900483B (en) | Anti-cd19 antibody formulations | |
| GB201612317D0 (en) | Antibody compositions | |
| IL271128A (en) | Novel anti-cd3 antibodies | |
| ZA201701461B (en) | Antibody formulations | |
| GB201610044D0 (en) | Antibodies | |
| GB201603291D0 (en) | Antibodies | |
| IL281976A (en) | Anti-fgfr2 antibody formulations | |
| GB201616699D0 (en) | Antibodies | |
| IL273529A (en) | Anti-pacap antibody | |
| HUE057615T2 (en) | Anti-il-22r antibodies | |
| IL283886A (en) | Antibody formulations | |
| IL263406B1 (en) | Anti-tnfrsf25 antibodies | |
| IL260083A (en) | Anti-myl9 antibody | |
| GB201709592D0 (en) | Antibody | |
| GB201622197D0 (en) | Antibodies | |
| GB201508257D0 (en) | Antibody formulations | |
| GB201620414D0 (en) | Antibodies | |
| GB201613158D0 (en) | Antibodies | |
| GB201612437D0 (en) | Anti-lag-3 antibodies | |
| GB201415526D0 (en) | Antibody Formulations |